Atherothrombosis is the most frequent underlying pathophysiological cause of ischemic heart and brain diseases, which are the main cause of death in Spain. One of the biggest challenges facing biomedical research in this area is identifying biomarkers that make it possible to predict cardiovascular events and define key molecules in atherothrombosis in order to develop new, safer and more effective therapeutic strategies.

In recent years, we've begun several clinical and experimental research projects focusing on the study of the most important inflammatory, pro-thrombotic and proteolytic factors in the atherothrombotic process.

The work of our group, which is made up of basic and clinical scientists, with the support of the CIMA services, is clearly oriented toward knowledge-based translational research. Our research therefore combines techniques from cell biology, molecular biology and biochemical tests, as well as preclinical and clinical approaches to define the molecular mechanisms that regulate the progression and tearing of the plaque, and to define their potential as biomarkers. The main objective is to prevent and treat the pathological vascular processes that lead to thrombosis.

The group's most recent research activity has made it possible to identify potential targets in thrombosis and vascular remodeling. We've carried out clinical trials in patients with atherothrombotic vascular disease, which have shown their usefulness as biomarkers in subclinical and clinical atherosclerosis, and their association with severity and a worse prognosis.

The design and synthesis of new series of small molecules capable of modifying the expression of these potential targets has allowed us to analyze their efficacy in the prevention of thrombosis and the control of bleeding in vitro and in vivo.

Currently, the main areas of research are the following:

  • Study of the importance of potential targets in experimental models of vascular stroke and evaluation of new cytoprotective strategies in the presence of comorbidities (atherosclerosis, age, diabetes).

  • Molecular, preclinical and clinical analysis of the effect of new small molecules with antithrombotic and anti-hemorrhagic properties.

  • Clinical research and validation of new biomarkers in patients with vascular ischemia.

"We've carried out clinical trials in patients with clinical and subclinical atherosclerosis, which suggest that MMP-10 may be a biomarker for vascular risk", Dra. Josune Orbe, Principal Investigator .

More information:


Nerea Cano
Avda. Pío XII, 55
31008 Pamplona

(+34) 948 194 700 Ext. 3044